{"product_id":"3sbio-business-model-canvas","title":"3SBio Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e3SBio's Business Model: A Strategic Deep Dive\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover the strategic engine driving 3SBio's success with our comprehensive Business Model Canvas. This detailed breakdown illuminates their customer relationships, revenue streams, and key resources, offering a clear roadmap to their market dominance.\u003c\/p\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind 3SBio's business model. This in-depth Business Model Canvas reveals how the company drives value, captures market share, and stays ahead in a competitive landscape. Ideal for entrepreneurs, consultants, and investors looking for actionable insights.\u003c\/p\u003e\n\u003cp\u003eSee how the pieces fit together in 3SBio’s business model. This detailed, editable canvas highlights the company’s customer segments, key partnerships, revenue strategies, and more. Download the full version to accelerate your own business thinking.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Companies and Biotech Firms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e3SBio actively cultivates key partnerships with other pharmaceutical and biotech firms. These collaborations are essential for broadening its product offerings and extending its market presence.  A prime example is the October 2024 agreement with Haihe Biopharma, granting 3SBio commercialization rights for Liporaxel, an oral paclitaxel solution, within China.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Pharma Giants (e.g., Pfizer)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e3SBio's strategic alliances with global pharmaceutical leaders are crucial. A prime example is the May 2025 agreement with Pfizer, granting them exclusive worldwide rights, excluding China, for the development, manufacturing, and commercialization of 3SBio's bispecific antibody, SSGJ-707.\u003c\/p\u003e\n\u003cp\u003eThis multi-billion dollar deal, encompassing an upfront payment and substantial potential milestone payments, underscores 3SBio's increasing global standing and its capacity to forge significant collaborations with major international pharmaceutical entities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch Institutions and Academic Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with research institutions and academic centers are crucial for 3SBio’s robust R\u0026amp;D efforts, driving the translation of scientific breakthroughs into novel therapeutic solutions. These partnerships are instrumental in conducting essential preclinical and clinical studies, thereby fostering the development of innovative new drugs.\u003c\/p\u003e\n\u003cp\u003eThese academic alliances contribute significantly to the scientific validation and the ultimate potential for clinical success of 3SBio's product candidates. For instance, in 2024, 3SBio announced a significant collaboration with a leading Chinese university to explore novel targets for autoimmune diseases, a field where academic research often pioneers new understanding.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e3SBio strategically partners with specialized commercialization and distribution firms to extend its market reach, particularly in emerging therapeutic sectors.  These collaborations are crucial for ensuring efficient product delivery and accessing varied customer bases.\u003c\/p\u003e\n\u003cp\u003eA key example of this strategy in action is 3SBio's 2024 agreement with Hybio Pharmaceutical, a Shenzhen-based company. This partnership focuses on the weight loss indication for their semaglutide injection, utilizing Hybio's e-commerce expertise to significantly improve patient access to the treatment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eEnhanced Market Penetration:\u003c\/strong\u003e Partnerships with distribution specialists allow 3SBio to enter new markets and therapeutic areas more effectively.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLeveraging E-commerce:\u003c\/strong\u003e The 2024 collaboration with Hybio Pharmaceutical highlights the use of online platforms to broaden patient access to semaglutide for weight loss.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOptimized Logistics:\u003c\/strong\u003e These alliances ensure that products reach diverse customer segments efficiently, improving overall supply chain performance.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Development and Manufacturing Organizations (CDMOs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e3SBio strategically engages with Contract Development and Manufacturing Organizations (CDMOs), both as a service provider and a potential client. This dual role enhances production flexibility and access to specialized manufacturing expertise, crucial for efficiently scaling drug development and commercialization.\u003c\/p\u003e\n\u003cp\u003eThe company's formal entry into the CDMO sector began in December 2021, signaling a commitment to leverage its manufacturing infrastructure and know-how. This move allows 3SBio to optimize its own production while also capturing opportunities within the broader biopharmaceutical manufacturing market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eCDMO Engagement:\u003c\/strong\u003e 3SBio operates within the CDMO space, offering and potentially utilizing manufacturing services.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Flexibility:\u003c\/strong\u003e This approach provides adaptability in production capacity and access to specialized manufacturing skills.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOperational Start:\u003c\/strong\u003e 3SBio officially commenced its CDMO operations in December 2021.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliances Drive Portfolio Expansion and Market Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e3SBio's key partnerships are vital for expanding its therapeutic portfolio and market reach. The company collaborates with both domestic and international pharmaceutical firms, research institutions, and specialized distribution partners. These alliances are designed to leverage complementary strengths, accelerate drug development, and ensure efficient market access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePartner Type\u003c\/th\u003e\n\u003cth\u003eExample Partnership\u003c\/th\u003e\n\u003cth\u003eYear\u003c\/th\u003e\n\u003cth\u003eKey Aspect\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmaceutical Firm (Co-development\/Commercialization)\u003c\/td\u003e\n\u003ctd\u003eHaihe Biopharma\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eChina commercialization rights for Liporaxel\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Pharmaceutical Leader\u003c\/td\u003e\n\u003ctd\u003ePfizer\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003ctd\u003eWorldwide rights (excl. China) for bispecific antibody SSGJ-707\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch Institution\u003c\/td\u003e\n\u003ctd\u003eLeading Chinese University\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eExploring novel targets for autoimmune diseases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercialization \u0026amp; Distribution Firm\u003c\/td\u003e\n\u003ctd\u003eHybio Pharmaceutical\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eWeight loss indication for semaglutide injection via e-commerce\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA detailed, data-driven Business Model Canvas for 3SBio, outlining its core operations, customer focus, and revenue streams.\u003c\/p\u003e\n\u003cp\u003eThis canvas provides a strategic overview for investors and stakeholders, highlighting 3SBio's market position and growth opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSaves hours of formatting and structuring your own business model by providing a clear, one-page snapshot for identifying core components and facilitating brainstorming.\u003c\/p\u003e\n\u003cp\u003eCondenses complex company strategy into a digestible format, perfect for comparing multiple models or creating fast executive summaries for quick review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development (R\u0026amp;D)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e3SBio's primary focus is on the extensive research and development of biopharmaceutical products. This encompasses everything from initial scientific investigation and laboratory testing to conducting human trials and securing regulatory approval for new medications.\u003c\/p\u003e\n\u003cp\u003eThe company maintains a strong pipeline, featuring 30 product candidates. Notably, as of December 2024, 29 of these candidates are innovative drugs being developed within Mainland China, highlighting a significant commitment to novel therapies.\u003c\/p\u003e\n\u003cp\u003eA key indicator of 3SBio's R\u0026amp;D progress is the advancement of its product candidates. Currently, 10 of these promising candidates have reached the critical Phase III clinical trial stage, suggesting they are nearing potential market introduction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Production\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e3SBio's core activities revolve around the manufacturing of its biopharmaceutical products, encompassing both recombinant protein therapies and other promising pharmaceutical candidates. The company strategically operates six production facilities, with a significant presence across China and Italy, ensuring a robust manufacturing footprint.\u003c\/p\u003e\n\u003cp\u003eMaintaining stringent quality control measures and optimizing production efficiency are paramount to 3SBio's operations. These efforts are critical for guaranteeing a consistent and reliable supply of life-saving therapies to patients worldwide. For instance, in 2023, 3SBio reported revenue of approximately RMB 7.6 billion, underscoring the scale and demand for its manufactured products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e3SBio's marketing and sales activities are centered on promoting its biopharmaceutical products across key therapeutic areas such as oncology, nephrology, and immunology. This involves a robust strategy to ensure widespread availability and adoption of their treatments.\u003c\/p\u003e\n\u003cp\u003eThe company utilizes an extensive nationwide sales and distribution network, which successfully reaches more than 11,000 hospitals and medical institutions throughout Mainland China. This broad reach is critical for market penetration and accessibility.\u003c\/p\u003e\n\u003cp\u003eStrong marketing initiatives have been instrumental in solidifying the market leadership of 3SBio's flagship products. For instance, TPIAO has consistently maintained a dominant position in its respective market segments, underscoring the effectiveness of these campaigns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trials and Regulatory Filings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eA core activity for 3SBio is the meticulous execution of clinical trials across all phases (I, II, and III) for its broad portfolio of novel therapeutics. This encompasses testing drugs for new medical conditions and entirely new chemical entities, such as the anti-IL-17A monoclonal antibody (mAb) targeting plaque psoriasis and the sustained-release erythropoietin, SSS06.\u003c\/p\u003e\n\u003cp\u003eSuccessful clinical trial outcomes are critical for advancing drug candidates through the regulatory process. Upon completion, 3SBio prepares and submits New Drug Applications (NDAs) to relevant health authorities, aiming for market approval and commercialization.\u003c\/p\u003e\n\u003cp\u003eThese regulatory submissions and subsequent approvals are vital for expanding 3SBio's product pipeline and market reach. For instance, as of early 2024, 3SBio has a robust pipeline with multiple drug candidates in various stages of clinical development, demonstrating their commitment to this key activity.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eConducting Phase I, II, and III clinical trials for innovative drug candidates.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eTesting new indications and novel compounds like anti-IL-17A mAb and long-acting erythropoietin (SSS06).\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePreparing and submitting New Drug Applications (NDAs) for regulatory review.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSecuring regulatory approvals to launch new products and expand market access.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Portfolio Expansion and Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003e3SBio strategically broadens its therapeutic reach by developing new treatments internally and forging external alliances, notably through licensing.  This approach allows the company to secure commercialization rights for innovative drugs, as demonstrated by its acquisition of rights for paclitaxel oral solution and Clifutinib during 2024.\u003c\/p\u003e\n\u003cp\u003eThese key activities are vital for diversifying 3SBio's product portfolio and enabling entry into new therapeutic areas and geographical markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eInternal R\u0026amp;D:\u003c\/strong\u003e Focus on developing novel therapies and improving existing ones.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLicensing Agreements:\u003c\/strong\u003e Acquire rights for promising drugs from other entities.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Partnerships:\u003c\/strong\u003e Collaborate with other companies for drug development and commercialization.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Entry:\u003c\/strong\u003e Leverage expanded therapeutic coverage to access new customer segments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharma's Journey: From Lab to Market Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e3SBio's key activities are centered on the rigorous development and manufacturing of biopharmaceutical products. This includes conducting extensive research and development, progressing drug candidates through clinical trials, and securing regulatory approvals. The company also focuses on robust manufacturing processes and effective marketing and sales strategies to bring its therapies to market.\u003c\/p\u003e\n\u003cp\u003eThe company’s commitment to innovation is evident in its pipeline, with 30 product candidates as of late 2024, 29 of which are novel drugs developed in China. Ten of these candidates have advanced to Phase III clinical trials, indicating significant progress towards potential market entry.\u003c\/p\u003e\n\u003cp\u003e3SBio operates six production facilities across China and Italy, ensuring a strong manufacturing base for its recombinant protein therapies and other pharmaceutical products. In 2023, the company generated approximately RMB 7.6 billion in revenue, reflecting the demand for its offerings.\u003c\/p\u003e\n\u003cp\u003eMarketing and sales efforts target key therapeutic areas like oncology, nephrology, and immunology, utilizing a vast distribution network that reaches over 11,000 hospitals in China. Flagship products, such as TPIAO, maintain strong market positions due to these initiatives.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003eKey Metrics\/Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development\u003c\/td\u003e\n\u003ctd\u003eDeveloping novel biopharmaceutical products, including innovative drugs and new chemical entities.\u003c\/td\u003e\n\u003ctd\u003e30 product candidates in pipeline (late 2024); 10 candidates in Phase III trials.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Trials\u003c\/td\u003e\n\u003ctd\u003eExecuting Phase I, II, and III trials for drug candidates, testing new indications and compounds.\u003c\/td\u003e\n\u003ctd\u003eTesting anti-IL-17A mAb for plaque psoriasis and SSS06 (sustained-release erythropoietin).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Affairs\u003c\/td\u003e\n\u003ctd\u003ePreparing and submitting New Drug Applications (NDAs) and securing market approvals.\u003c\/td\u003e\n\u003ctd\u003eMultiple drug candidates in various stages of clinical development (early 2024).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eProducing recombinant protein therapies and other pharmaceutical candidates across six facilities.\u003c\/td\u003e\n\u003ctd\u003eRevenue of RMB 7.6 billion in 2023; facilities in China and Italy.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketing \u0026amp; Sales\u003c\/td\u003e\n\u003ctd\u003ePromoting products in oncology, nephrology, and immunology through an extensive distribution network.\u003c\/td\u003e\n\u003ctd\u003eReaching over 11,000 hospitals in China; TPIAO's market leadership.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBusiness Development\u003c\/td\u003e\n\u003ctd\u003eExpanding therapeutic reach through internal R\u0026amp;D and external licensing agreements.\u003c\/td\u003e\n\u003ctd\u003eAcquired rights for paclitaxel oral solution and Clifutinib in 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe 3SBio Business Model Canvas you are previewing is precisely the same document you will receive upon purchase. This is not a sample or a mockup, but a direct representation of the complete, ready-to-use file. You'll gain full access to this exact Business Model Canvas, allowing you to immediately begin refining your strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55611165442425,"sku":"3sbio-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/3sbio-business-model-canvas.png?v=1754752100","url":"https:\/\/growthsharematrix.com\/products\/3sbio-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}